Company Profile
Tango Therapeutics Stock Price, News & Analysis
- Ticker:
- TNGX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
29.00 USD (+0.73%)
Close
Last updated: August 6, 2026
3.11B USD
Market cap
Why the stock is moving
The latest monitored company update is “Tango Therapeutics Announces Executive Chair Transition.” The corresponding closing-price reaction is not yet available.
Company overview
Synthetic Lethality Oncology Company
Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor suppressor loss.
Vopimetostat
Vopimetostat is a brain-penetrant MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in RAS-mutant tumors.
RAS(ON) Combination Strategy
The company is combining vopimetostat with daraxonrasib or zoldonrasib in pancreatic and lung cancers carrying both MTAP deletion and RAS mutations.
Future catalysts
Initial clinical data from the vopimetostat and RAS(ON) inhibitor combination study are expected during 2026.
Tango plans to provide details of a potential registrational strategy when the combination data are presented.
Recent news
- 01
Tango Therapeutics Announces Executive Chair Transition
Source: Tango Therapeutics
- 02
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Source: Tango Therapeutics
- 03
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Source: Tango Therapeutics
- 04
Tango Therapeutics Announces Proposed $500 Million Public Offering
Source: Tango Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tango Therapeutics (TNGX)?
Tango Therapeutics (TNGX) most recently closed at 29.00 USD, a +0.73% move versus the previous session.
What is the market cap of Tango Therapeutics (TNGX)?
Tango Therapeutics currently has a market capitalization of 3.11B USD on BioPharmSignal.
What does Tango Therapeutics do?
Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in RAS-mutant...
On which exchange is TNGX stock listed?
Tango Therapeutics (TNGX) is associated with NASDAQ, United States, Biopharma.
What is vopimetostat?
Initial clinical data from the vopimetostat and RAS(ON) inhibitor combination study are expected during 2026.
Which conditions is Tango Therapeutics targeting with vopimetostat?
Tango Therapeutics is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Tango Therapeutics describe recent progress with vopimetostat?
Initial clinical data from the vopimetostat and RAS(ON) inhibitor combination study are expected during 2026.
What is Synthetic?
Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor suppressor loss.